||EPS - Basic
||Market Cap (m)
Arthro Kinetics Share Discussion Threads
Showing 451 to 474 of 475 messages
|Well what about that then boys and girls, no big stars, boring if you're not a fan but a European final, well done to the famous Glasgow Rangers....... I know all you tims will be happy for me............|
|By jove the market likes this news. FDA approval.
Its an improvement and there are some promising bits but it looks like they'll need more cash soon. Cash minus debt is very low.|
|Medtronic to acquire Kyphon for $3.9 billion
Medtronic's spinal focus has been on providing treatment options for younger patients who are suffering from scoliosis and degenerative disc disease in the cervical and lumbar spine. It primarily serves orthopedic and neurological surgeons who specialize in spinal surgery.
Kyphon's focus has been on treating older patients suffering from vertebral compression fractures and spinal stenosis.
Joanne Wuensch, an analyst with BMO Capital Markets, said in a research report, "We believe that this acquisition is an excellent fit for Medtronic, combining leading technology, a rapidly growing top line, a top-notch sales presence, and creating a stronghold in the spinal industry."
|Market isnt too pleased so far. Agree interims should give clearer picture
|Yes, but on first reading it seems all a bit too historical.
Certainly heavy going. Will have another go later, but it
may take the next interims (within the next 3 months) to
get a proper picture of where thier tradng/finances
are now, post the re-financing...|
|katie - you got your reality check :(|
|A few more buys and we will be back to last weeks level.Anyone thinking of selling hold on as long as you can to get the best price.|
|The run up to results and the results will push the price back up to and above the 20 pence level.The pull back in price last week was on very low volume and the price was rising on very small buys.|
|Finals by the end of this month (6month period is up).
Those numbers should provide a reality check...|
|More buying today very early in the day.Looking to top up before the next move up.|
|Arthro Kinetics European Patent
Arthro Kinetics plc
13 June 2007
Arthro Kinetics plc - granted European patent
WEDNESDAY, 13th June 2007 - Arthro Kinetics plc (AIM: AKI) ("Arthro Kinetics"),
the orthopedics company dedicated to regenerating joint mobility and spinal disc
function, announces that its wholly owned subsidiary Arthro Kinetics AG has been
granted a European patent (EP 1 289 574) for "Cartilage Replacement and Methods
for the Production Thereof".
Jason Loveridge, CEO of Arthro Kinetics commented:
"This is excellent news for Arthro Kinetics and validation of the novelty of our
R&D and product portfolio for cartilage regeneration. This patent extends
coverage for our core proprietary technology - from which our first product
CaReS(R) emerged onto the market in 2003 - to an additional 19 European
countries beyond Germany, where the original application was filed in May 2001.
We are continuing to pursue protection across all key commercial markets and, in
this respect, the European patent represents an important piece of intellectual
property protecting our core technology and portfolio of products for cartilage
Jason Loveridge Tel: +49 (0)711 305 110 70
Chief Executive, Arthro Kinetics plc|
|It looks like someone is buying in 50,000 chunks|
|This looks like a rise up to possible resistance at 22 pence is now on the cards as it does not take much buying to move the price.|
|Up 2p today on this news
Expands Chinese Agreement
Japan Licence Agreement
|Looks like you've done it agin huge|
|Yeah Ive no doubt theres been some cash burn. Im not prepared to take a 100% hit though so Ill see what the next results bring. I think their technology should have value; they seem to have chucked a lot of cash developing/marketing it. And its rare just now to see biotechs trading at around cash value. When Ive bought previously at this kind of valuation Ive done pretty well ie. Aortech and more recently Asterand.|
|Always a good sign when Huge arrives looking for value.
But caution Huge. AKI spend alot on trying to shift
their product. I doubt £6m is still left...|
|I bought some of these a few weeks back. Market cap £7.5M, cash £6M. A bit of a punt but risk/reward looks pretty good.|
|Are these a takeover target ?
Some large director purchases?|
Knee implant offers hope for cartilage repair
By Katherine Griffiths
Last Updated: 10:19pm BST 06/04/2007
A small orthopaedics company has developed a product which can be implanted into the knee to encourage the body to repair or grow more cartilage.
Arthro Kinetics, which is based in Germany and listed in London, said pigs had responded well to its new device. The company aims to have the product approved and on the market by the end of the year. Orthopaedics companies are trying to develop devices which can be implanted in patients who are still quite active to delay or put off completely the need for a metal joint replacement.
Modern hip and knee replacements on the market require patients to go to hospital to have cells removed from their joints. These are then grown in a laboratory for several weeks before being injected back into the body as part of the replacement device.
Arthro hopes to simplify the process. It is working on a product which would not require patients to go to hospital for the initial removal of cells. Instead, a collagen product would be implanted in the knee which would be able to encourage cells to grow more cartilage. It is also working on a version for ankles.
Jason Loveridge, chief executive of Arthro, said cutting out the need for the initial biopsy would make the process easier for the patient and would also cut the cost to health services.
"You wouldn't have to see the doctor twice. You also wouldn't require culturing, which needs a building and scientists, and the biopsy is not sterile so there is a risk of infection."
Joint replacements have been a big growth area in Europe and the US as people have been living longer and getting fatter.
One area companies have been working in is creating devices using the patient's own cells to encourage cartilage to grow again.
The National Institute for Clinical Excellence is waiting to see how effective modern joint replacements or enhancements are before making them widely available on the NHS.
|Basically, the share is now down to cash-value. Historic cash-burn has however been high, so could yet see a discount to cash, if good news proves elusive. At this point some very carefull analysis of 2007 trading prospects is required. How much cash out, and how much in... Any volunteers?...|